The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence


Affiliations
1 Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, India
2 Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India
3 Department of ENT, Trustwell Hospitals, Bangalore, India
4 Department of ENT, Jagtap Hospital, Dhule, India
5 Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, India
6 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
     

   Subscribe/Renew Journal


Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.

Keywords

Recurrent Aphthous Stomatitis, Rebamipide.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Rivera C. Essentials of recurrent aphthous stomatitis (Review). Biomed Rep. 2019 Aug;11:47-50.

  • Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers, Dtsch Arztebl Int. 2014 Oct;111:665–73.

  • Sánchez-Bernal J, Conejero C, Conejero R. Aftosis oral recidivante recurrent Aphthous Stomatitis. Actas Dermo-Sifiliográficas. 2020 Aug;111(6): 471-80.

  • Akintoye SO, Greenberg MS. Recurrent Aphthous Stomatitis. Dent Clin North Am. 2014 Apr;58(2):281–97.

  • Karambelkar MV, Ashwinirani SR, Sande A, Kamala KA. Comparative study of occurrence of recurrent aphthous sto matitis during exam stress and relaxed phase in dental college students of Krishna Institute of Medical Sciences. BLDE Univ J Health Sci. 2020 Dec;5(2):173-7.

  • Tarakji B, Gazal G, Al-Maweri SA, Azzeghaiby SN, Alaizari N. Guideline for the Diagnosis and Treatment of Recurrent Aphthous Stomatitis for Dental Practitioners. J Int Oral Health 2015 May;7(5):74-80.

  • Khurshid AM, Nagaraj K. Herpetiform Ulceration Involving Pharynx – Case Report. J Dental Sci. 2017 Oct;2(6):1-3.

  • Slezakova S, Linhartova PB, Bartova J, Petanova J, Kuklinek P, Fassmann A, Dusek L, Holla LI. Gene variability in matrix metalloproteinases in patients with recurrent aphthous stomatitis. J Oral Pathol Med. 2020 Mar;49(3):271–77.

  • Linhartova PB, Janos J, Slezakova S, Bartova J, Petanova J, Kuklinek P, Fassmann A, Dusek L, Holla LI. Recurrent aphthous stomatitis and gene variability in selected interleukins: a case–control study. Eur J Oral Sci. 2018 Dec;126(6):485-92.

  • Parssinen M, Jäsberg H, Mikkonen JJW, Kullaa AM. Oral mucosal pellicle as an immune protection against micro-organisms in patients with recurrent aphthous stomatitis: A hypothesis. Med Hypotheses. 2021 Jan;146:110449.

  • Cakir E. Is there any relationship between recurrent oral aphthous stomatitis and prediabetes?. Med Hypotheses. 2013 Sep;81(3):512-3.

  • Bagan J, Saez G, Tormos C, Gavalda C, Sanchis JM, Bagan L, Scully C. Oxidative stress and recurrent aphthous stomatitis. Clin Oral Investig. 2014 Nov;18(8):1919-23.

  • Aminabadi NA. Recurrent aphthous stomatitis may be initiated by traumatic epithelial implantation and sustained by localized pathergic status. Med Hypotheses. 2008;70(3):522-4.

  • Field EA, Allan RB. Oral ulceration – Aetiopathogenesis, Clinical Diagnosis and Management in the Gastrointestinal Clinic. Aliment Pharmacol Ther. 2003 Nov;18(10):949-62.

  • Motahari P, Pournagi-Azar F, Khodadadi P. Role of tumor necrosis factor-alpha in pathogenesis of recurrent aphthous stomatitis: A systematic review and meta-analysis. J Oral Health Oral Epidemiol. 2020 Jul;9(3):108-15.

  • Archana JP, Prabhakaran AC. Pharmacotherapy of recurrent aphthous ulcers. Chron Young Sci. 2011 Jan;2(3):134-8.

  • Vivek V, Nair BJ. Recurrent aphthous stomatitis: current concepts in diagnosis and Management. J Indian Acad Oral Med Radiol. 2011 Jul;23(3):232-36.

  • Katz J, Langevitz P, Shemer J, Barak S, Livneh A. Prevention of recurrent aphthous stomatitis with Colchicine: an open trial. J Am Acad Dermatol. 1994 Sep;31(3):459-61.

  • Sridhar T, Elumalai M, Karthika B. Recurrent aphthous stomatitis: A review. Biomed Pharmacol J. 2013;6(1):17-22.

  • Halboub E, Al-Maweri SA, Parveen S, Al-Wesabi M, Al-Sharani HM, Al-Sharani A, Al-Kamel A, Albashari A, Shamala A. Zinc Supplementation for Prevention and Management of Recurrent Aphthous Stomatitis: A Systematic Review, J Trace Elem Med Bio. 2021 Dec;68:126811.

  • Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S. Antiulcer mechanism of action of Rebamipide, Anovel antiulcer compound, on DiethyldithiocarbamateInduced antral gastric ulcers in rats. Eur J Pharmacol. 1992 Feb;212(1):9-13.

  • Kudur MH, Hulmani M. Rebamipide: A novel agent in the treatment of recurrent aphthous ulcer and Behcet’s Syndrome. Indian J Dermatol. 2013 Oct;58(5):352–54.

  • Li W, Zhao Y, Xu X, Ma W, Gao P, Wang Y, Liang K, Li R. Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J. 2015 Jun;282(12):2317-26.

  • Tajima K, Hattori T, Takahashi H, Katahira H, Niramatsu A, Kumakura S, Goto H.Rebamipidesuppresses TNF-α production and macrophage infiltration in the Conjunctiva. Vet Ophthalmol. 2018 Jul;21(4):347-52.

  • Naito Y, Yoshikawa T.Rebamipide: Agastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3);261-70.

  • Kesavalingam K, Sivakumar V, Meera SS, Karthikeyan T, Vijayanand, Venkateshwar R. A prospective study on efficacy of Rebamipide in recurrent aphthous stomatitis. IOSR Journal of Dental and Medical Sciences. 2017 Oct;16(10):44-5.

  • Uppalwar P, Kunjir G, Krishna Kumar R, Chandwani R, Kelgandre D, Donempudi P. Comparison of therapeutic effect of topical Amlexanox (5%), and oral Rebamipide (100 mg) in the management of oral apthousulceration. Journal of Oral and Dental Health. 2016;2(1):6-8.

  • Jadhav A, Marathe S, Mhapuskar A, Jadhav S, Thopte S, Vhatakar P. To evaluate the efficacy of Rebamipide on clinical resolution and recurrence of minor recurrent aphthous stomatitis. Int J Dent Health Sci. 2015 Jan;2(4):781-97.

  • Parvathi Devi MK, Ramesh DN, Koppal S, Byatnal AR, Rukmangada T, Byatnal AA. Efficacy of Rebamipide and Levamisole in the treatment of patients with recurrent aphthous ulcer - acomparative study. J Clin Diagn Res. 2014 Nov;8(11):ZC119–ZC122.

  • Hasan S, Perween N, Saeed S, Mandeep K, Gombra V, Rai A. Evaluation of 5% Amlexenoxoral paste and Rebamipidetablets in treatment of recurrent apthousstomatitis and comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2020 Apr. DOI: doi.org/10.1007/s12070-02001858-1

  • Singh A, Adil HA, Umarji HR. Evaluation of the efficacy of topical Amlexanoxoral paste and Rebamipidetablets in the management of recurrent Aphthous Ulcers. Int J Curr Res. 2018 Jul;10(7):71105-8.


Abstract Views: 303

PDF Views: 0




  • Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence

Abstract Views: 303  |  PDF Views: 0

Authors

K. R. Meghanadh
Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, India
Mandeep Kaur
Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India
Deepak Haldipur
Department of ENT, Trustwell Hospitals, Bangalore, India
Charuhas Jagtap
Department of ENT, Jagtap Hospital, Dhule, India
N. K. Soni
Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, India
Ashwin Kotamkar
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Aaditi Phadke
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Parthasarathy Muralidharan
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Amit Qamra
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India

Abstract


Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.

Keywords


Recurrent Aphthous Stomatitis, Rebamipide.

References